November 21, 2026

Beximco Pharma concerned by its falling share price at DSE

The management of the Beximco Pharmaceuticals Ltd. is concerned by the declining trend of its share prices at the Dhaka Stock Exchange (DSE) against almost stable rate at the London Stock Exchange (LSE).

bdnews24.com News Service

bdnews24.com

Published : 08 Jan 2006, 06:00 PM

Updated : 17 Aug 2022, 05:40 PM

Dhaka, Jan 9 (BDNEWS) – The management of the Beximco Pharmaceuticals Ltd. is concerned by the declining trend of its share prices at the Dhaka Stock Exchange (DSE) against almost stable rate at the London Stock Exchange (LSE). The company issued 20 million Global Depository Receipts (GDRs) through the Alternative Investment Market (AIM) of LSE from the international investors. The company raised $21 million from the LSE, which was 45 percent of its target of $46.7 million. On the opening day of trading at GDRs, the share price of Beximco Pharma at the DSE was almost similar to that in LSE. But it started declining in the following two months. The share prices of GDR in the LSE was equivalent to Tk 77.1 on October 21, and was Tk 76.8 on December 29, 2005, while at the DSE, the share price was Tk 74.9 on October 20 and was Tk 58.00 on December 29, according to a study of the Centre for Policy Dialogue (CPD). "We don't know why the share price is falling at DSE ... If any investor at LSE asks us about the falling price at DSE, it would be difficult to answer," Nazmul Hasan, chief executive officer (CEO) of Beximco Pharma, told BDNEWS. He added: "We have excellent growth performance in recent times and are executing our planned programmes." CPD Research Fellow Khondoker Golam Moazzem said the price difference between GDRs and Beximco Pharma shares at DSE was less than three percent when the trading of GDRs began at LSE. Since the share price of the company was seven times higher than its face value at the DSE, the management, based on that price, started its trading in LSE, he added. The CPD study noted that the price of Beximco Pharma shares increased at the DSE for two months before its trading started formally at the LSE, but started declining afterwards. The price deflection between the two markets reached about 32 percent after two months. "Such movement of price might have happened due to investors' high expectation about the company's prospects, which may have declined later due to less than expected international response," Moazzem said. He said the price deflection could also be caused by the problem of asymmetric information between the two markets. Mirza Azizul Islam, Chairman of the Securities and Exchange Commission (SEC), said: "The decline in the price of Beximco Pharma shares at the DSE could be caused by less than expected response from international investors." "Lack of confidence among the investors might have caused this price differential," said Saiful Islam, Managing Director of the Equity Partners and Securities Ltd. The company's earning per share (EPS) was Tk 5.26 and its net profit after tax stood at 294.30 during in 2004. BDNEWS/1745 hrs.
Related Stories